CXCR2: a target for pancreatic cancer treatment?

Bibliography

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29
   PubMed Web of Science ®Google Scholar
• Hines OJ, Reber HA. Pancreatic surgery. Curr Opin Gastroenterol 2008;24:603-11
   PubMedGoogle Scholar
• Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13
   PubMed Web of Science ®Google Scholar
• Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72
   PubMed Web of Science ®Google Scholar
• Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2012; published online 30 October 2012; doi:10.1136/gutjnl-2012-303588
   Google Scholar
• Heinemann V, Labianca R, Hinke A, Louvet C. Increased survival using platinum analog combined with gemcitabine as compared to single-agent gemcitabine in advanced pancreatic cancer: pooled analysis of two randomized trials, the GERCOR/GISCAD intergroup study and a German multicenter study. Ann Oncol 2007;18:1652-9
   PubMed Web of Science ®Google Scholar
• Kindler HL, Niedzwiecki D, Hollis D, et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J Clin Oncol 2010;28:3617-22
   PubMed Web of Science ®Google Scholar
• Kindler HL, Wroblewski K, Wallace JA, et al. Gemcitabine plus sorafenib in patients with advanced pancreatic cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest New Drugs 2012;30:382-6
   PubMed Web of Science ®Google Scholar
• O'Reilly EM, Niedzwiecki D, Hall M, et al. A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). Oncologist 2010;15:1310-19
   PubMed Web of Science ®Google Scholar
• Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011;364:1817-25
   PubMed Web of Science ®Google Scholar
• Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45
   PubMed Web of Science ®Google Scholar
• Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease. World J Gastroenterol 2008;14:378-89
   PubMed Web of Science ®Google Scholar
• Iwama T. NSAIDs and colorectal cancer prevention. J Gastroenterol 2009;44(Suppl 1):72-6
   PubMedGoogle Scholar
• Duell EJ, Casella DP, Burk RD, et al. Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2006;15:726-31
   PubMed Web of Science ®Google Scholar
• Vendramini-Costa DB, Carvalho JE. Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 2012;18:3831-52
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44
   PubMed Web of Science ®Google Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7
   PubMed Web of Science ®Google Scholar
• Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004;4:1-8
   Google Scholar
• Gabrilovich DI, Bronte V, Chen S-H, et al. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007;67:425
   Google Scholar
• Yang L, DeBusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21
   PubMed Web of Science ®Google Scholar
• Shojaei F, Wu X, Zhong C, et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007;450:825-31
   PubMed Web of Science ®Google Scholar
• Stadtmann A, Zarbock A. CXCR2: from bench to bedside. Front Immunol 2012; published online 24 August 2012; doi: 10.3389/fimmu.2012.00263
   PubMedGoogle Scholar
• Veenstra M, Ransohoff RM. Chemokine receptor CXCR2: physiology regulator and neuroinflammation controller? J Neuroimmunol 2012;246:1-9
   PubMedGoogle Scholar
• Gabellini C, Trisciuoglio D, Desideri M, et al. Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer 2009;45:2618-27
   PubMed Web of Science ®Google Scholar
• Baier PK, Wolff-Vorbeck G, Eggstein S, et al. Cytokine expression in colon carcinoma. Anticancer Res 2005;25:2135-9
   PubMed Web of Science ®Google Scholar
• Singh S, Singh AP, Sharma B, et al. CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 2010;6:111-16
   PubMed Web of Science ®Google Scholar
• Ohri CM, Shikotra A, Green RH, et al. Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer. BMC Cancer 2010;10:172-81
   PubMedGoogle Scholar
• Reiland J, Furcht LT, McCarthy JB. CXC-chemokines stimulate invasion and chemotaxis in prostate carcinoma cells through the CXCR2 receptor. Prostate 1999;41:78-88
   PubMedGoogle Scholar
• Liu Z, Yang L, Xu J, et al. Enhanced expression and clinical significance of chemokine receptor CXCR2 in hepatocellular carcinoma. J Surg Res 2011;166:241-6
   Google Scholar
• Mestas J, Burdick MD, Reckamp K, et al. The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol 2005;175:5351-7
   PubMed Web of Science ®Google Scholar
• Wang B, Hendricks DT, Wamunyokoli F, Parker MI. A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. Cancer Res 2006;66:3071-7
   PubMed Web of Science ®Google Scholar
• Matsuo Y, Ochi N, Sawai H, et al. CXCL8/IL-8 and CXCL12/SDF-1alpha co-operatively promote invasiveness and angiogenesis in pancreatic cancer. Int J Cancer 2009;124:853-61
   PubMedGoogle Scholar
• Yang G, Rosen DG, Liu G, et al. CXCR2 promotes ovarian cancer growth through dysregulated cell cycle, diminished apoptosis, and enhanced angiogenesis. Clin Can Res 2010;16:3875-86
   PubMed Web of Science ®Google Scholar
• Han L, Jiang B, Wu H, et al. High expression of CXCR2 is associated with tumorigenesis, progression, and prognosis of laryngeal squamous cell carcinoma. Med Oncol 2012;29:2466-72
   PubMedGoogle Scholar
• Li A, Cheng XJ, Moro A, et al. CXCR2-Dependent endothelial progenitor cell mobilization in pancreatic cancer growth. Transl Oncol 2011;4:20-8
   PubMedGoogle Scholar
• Li A, King J, Moro A, et al. Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer. Am J Pathol 2011;178:1340-9
   PubMed Web of Science ®Google Scholar
• Wente MN, Keane MP, Burdick MD, et al. Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis. Cancer Lett 2006;241:221-7
   PubMed Web of Science ®Google Scholar
• Guha S, Eibl G, Kisfalvi K, et al. Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 2005;65:2738-45
   PubMed Web of Science ®Google Scholar
• Bacon K, Baggiolini M, Broxmeyer H, et al. Chemokine/chemokine receptor nomenclature. J Interferon Cytokine Res 2002;22:1067-8
   PubMed Web of Science ®Google Scholar
• Baggiolini M, Dewald B, Moser B. Interleukin-8 and related chemotactic cytokines–CXC and CC chemokines. Adv Immunol 1994;55:97-179
   PubMed Web of Science ®Google Scholar
• Murphy PM, Baggiolini M, Charo IF, et al. International union of pharmacology. XXII. Nomenclature for chemokine receptors. Pharmacol Rev 2000;52:145-76
   PubMed Web of Science ®Google Scholar
• Murphy PM, Tiffany HL. Cloning of complementary DNA encoding a functional human interleukin-8 receptor. Science 1991;253:1280-3
   PubMed Web of Science ®Google Scholar
• Matsushima K, Morishita K, Yoshimura T, et al. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin 1 and tumor necrosis factor. J Exp Med 1988;167:1883-93
   PubMed Web of Science ®Google Scholar
• Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002;283:R7-28
   PubMed Web of Science ®Google Scholar
• Rot A, Von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928
   PubMed Web of Science ®Google Scholar
• Cacalano G, Lee J, Kikly K, et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 1994;265:682-4
   PubMed Web of Science ®Google Scholar
• Heidemann J, Ogawa H, Dwinell MB, et al. Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem 2003;278:8508-15
   PubMed Web of Science ®Google Scholar
• Strieter RM, Burdick MD, Mestas J, et al. Cancer CXC chemokine networks and tumour angiogenesis. Eur J Cancer 2006;42:768-78
   PubMed Web of Science ®Google Scholar
• Sparmann A, Bar-Sagi D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell 2004;6:447-58
   PubMed Web of Science ®Google Scholar
• Tecimer T, Dlott J, Chuntharapai A, et al. Expression of the chemokine receptor CXCR2 in normal and neoplastic neuroendocrine cells. Arch Pathol Lab Med 2000;124:520-5
   PubMedGoogle Scholar
• Allen SJ, Crown SE, Handel TM. Chemokine: receptor structure, interactions, and antagonism. Annu Rev Immunol 2007;25:787-820
   PubMed Web of Science ®Google Scholar
• Nasser MW, Raghuwanshi SK, Malloy KM, et al. CXCR1 and CXCR2 activation and regulation. Role of aspartate 199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor internalization. J Biol Chem 2007;282:6906-15
   Google Scholar
• Palczewski K, Kumasaka T, Hori T, et al. Crystal structure of rhodopsin: a G protein-coupled receptor. Science 2000;289:739-45
   PubMed Web of Science ®Google Scholar
• Deupi X, Standfuss J. Structural insights into agonist-induced activation of G-protein-coupled receptors. Curr Opin Struct Biol 2011;21:541-51
   PubMed Web of Science ®Google Scholar
• Murphy PM. Chemokines and the molecular basis of cancer metastasis. N Engl J Med 2001;345:833-5
   PubMed Web of Science ®Google Scholar
• Raman D, Baugher PJ, Thu YM, Richmond A. Role of chemokines in tumor growth. Cancer Lett 2007;256:137-65
   PubMed Web of Science ®Google Scholar
• Singh S, Sadanandam A, Singh RK. Chemokines in tumor angiogenesis and metastasis. Cancer Metastasis Rev 2007;26:453-67
   PubMed Web of Science ®Google Scholar
• Murdoch C, Finn A. Chemokine receptors and their role in inflammation and infectious diseases. Blood 2000;95:3032-43
   PubMed Web of Science ®Google Scholar
• Zlotnik A, Yoshie O. Chemokines: a new classification system and their role in immunity. Immunity 2000;12:121-7
   PubMed Web of Science ®Google Scholar
• Rainczuk A, Rao J, Gathercole J, Stephens AN. The emerging role of CXC chemokines in epithelial ovarian cancer. Reproduction 2012;144:303-17
   PubMedGoogle Scholar
• Ahuja SK, Murphy PM. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor. J Biol Chem 1996;271:20545-50
   PubMed Web of Science ®Google Scholar
• Saurer L, Reber P, Schaffner T, et al. Differential expression of chemokines in normal pancreas and in chronic pancreatitis. Gastroenterololgy 2000;118:356-67
   PubMedGoogle Scholar
• Takamori H, Oades ZG, Hoch OC, et al. Autocrine growth effect of IL-8 and GROalpha on a human pancreatic cancer cell line, Capan-1. Pancreas 2000;21:52-6
   PubMed Web of Science ®Google Scholar
• Baggiolini M. Chemokines and leukocyte traffic. Nature 1998;392:565-8
   PubMed Web of Science ®Google Scholar
• Zarbock A, Ley K. Mechanisms and consequences of neutrophil interaction with the endothelium. Am J Pathol 2008;172:1-7
   PubMed Web of Science ®Google Scholar
• Sunahara RK, Dessauer CW, Gilman AG. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 1996;36:461-80
   PubMed Web of Science ®Google Scholar
• Rodriguez-Viciana P, Warne PH, Dhand R, et al. Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 1994;370:527-32
   PubMed Web of Science ®Google Scholar
• Monteclaro FS, Charo IF. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. J Biol Chem 1996;271:19084-92
   PubMed Web of Science ®Google Scholar
• Crump MP, Gong JH, Loetscher P, et al. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J 1997;16:6996-7007
   PubMed Web of Science ®Google Scholar
• Rajagopalan L, Rajarathnam K. Ligand selectivity and affinity of chemokine receptor CXCR1. Role of N-terminal domain. J Biol Chem 2004;279:30000-8
   PubMedGoogle Scholar
• Kraemer S, Lue H, Zernecke A, et al. MIF-chemokine receptor interactions in atherogenesis are dependent on an N-loop-based 2-site binding mechanism. FASEB J 2011;25:894-906
   PubMed Web of Science ®Google Scholar
• Prado GN, Suetomi K, Shumate D, et al. Chemokine signaling specificity: essential role for the N-terminal domain of chemokine receptors. Biochemistry 2007;46:8961-8
   PubMed Web of Science ®Google Scholar
• Baugher PJ, Richmond A. The carboxyl-terminal PDZ ligand motif of chemokine receptor CXCR2 modulates post-endocytic sorting and cellular chemotaxis. J Biol Chem 2008;283:30868-78
   PubMedGoogle Scholar
• Wu Y, Wang S, Farooq SM, et al. A chemokine receptor CXCR2 macromolecular complex regulates neutrophil functions in inflammatory diseases. J Biol Chem 2012;287:5744-55
   PubMedGoogle Scholar
• Knall C, Young S, Nick JA, et al. Interleukin-8 regulation of the Ras/Raf/mitogen-activated protein kinase pathway in human neutrophils. J Biol Chem 1996;271:2832-8
   PubMed Web of Science ®Google Scholar
• Schraufstatter IU, Chung J, Burger M. IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol 2001;280:L1094-103
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan G, Salgia R, Groopman JE. Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 2000;275:6868-75
   PubMed Web of Science ®Google Scholar
• Davis RJ. Transcriptional regulation by MAP kinases. Mol Reprod Dev 1995;42:459-67
   PubMedGoogle Scholar
• Keely PJ, Westwick JK, Whitehead IP, et al. Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness through PI(3)K. Nature 1997;390:632-6
   PubMed Web of Science ®Google Scholar
• Itoh K, Yoshioka K, Akedo H, et al. An essential part for Rho-associated kinase in the transcellular invasion of tumor cells. Nat Med 1999;5:221-5
   PubMed Web of Science ®Google Scholar
• Schmitz AA, Govek EE, Bottner B, Van Aelst L. Rho GTPases: signaling, migration, and invasion. Exp Cell Res 2000;261:1-12
   PubMed Web of Science ®Google Scholar
• Eash KJ, Greenbaum AM, Gopalan PK, Link DC. CXCR2 and CXCR4 antagonistically regulate neutrophil trafficking from murine bone marrow. J Clin Invest 2010;120:2423-31
   PubMed Web of Science ®Google Scholar
• Von Vietinghoff S, Asagiri M, Azar D, et al. Defective regulation of CXCR2 facilitates neutrophil release from bone marrow causing spontaneous inflammation in severely NF-kappa B-deficient mice. J Immunol 2010;185:670-8
   PubMedGoogle Scholar
• Mei J, Liu Y, Dai N, et al. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and neutrophil homeostasis in mice. J Clin Invest 2012;122:974-86
   PubMed Web of Science ®Google Scholar
• Zaja-Milatovic S, Richmond A. CXC chemokines and their receptors: a case for a significant biological role in cutaneous wound healing. Histol Histopathol 2008;23:1399-407
   PubMed Web of Science ®Google Scholar
• Liu L, Belkadi A, Darnall L, et al. CXCR2-positive neutrophils are essential for cuprizone-induced demyelination: relevance to multiple sclerosis. Nat Neurosci 2010;13:319-26
   PubMed Web of Science ®Google Scholar
• Traves SL. Increased levels of the chemokines GROalpha and MCP-1 in sputum samples from patients with COPD. Thorax 2002;57:590-5
   PubMed Web of Science ®Google Scholar
• Qiu Y, Zhu J, Bandi V, et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:968-75
   PubMed Web of Science ®Google Scholar
• Sue RD, Belperio JA, Burdick MD, et al. CXCR2 is critical to hyperoxia-induced lung injury. J Immunol 2004;172:3860-8
   PubMedGoogle Scholar
• Strieter RM, Keane MP, Burdick MD, et al. The role of CXCR2/CXCR2 ligands in acute lung injury. Curr Drug Targets Inflamm Allergy 2005;4:299-303
   PubMedGoogle Scholar
• Miller AL, Strieter RM, Gruber AD, et al. CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction. J Immunol 2003;170:3348-56
   PubMed Web of Science ®Google Scholar
• Stevenson CS, Coote K, Webster R, et al. Characterization of cigarette smoke-induced inflammatory and mucus hypersecretory changes in rat lung and the role of CXCR2 ligands in mediating this effect. Am J Physiol Lung Cell Mol Physiol 2005;288:L514-22
   PubMed Web of Science ®Google Scholar
• Chapman RW, Minnicozzi M, Celly CS, et al. A novel, orally active CXCR1/2 receptor antagonist, Sch527123, inhibits neutrophil recruitment, mucus production, and goblet cell hyperplasia in animal models of pulmonary inflammation. J Pharmacol Exp Ther 2007;322:486-93
   PubMed Web of Science ®Google Scholar
• Cummings CJ, Martin TR, Frevert CW, et al. Expression and function of the chemokine receptors CXCR1 and CXCR2 in sepsis. J Immunol 1999;162:2341-6
   PubMed Web of Science ®Google Scholar
• Ness TL, Hogaboam CM, Strieter RM, Kunkel SL. Immunomodulatory role of CXCR2 during experimental septic peritonitis. J Immunol 2003;171:3775-84
   PubMedGoogle Scholar
• Kempf T, Zarbock A, Widera C, et al. GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice. Nat Med 2011;17:581-8
   PubMed Web of Science ®Google Scholar
• Block H, Herter JM, Rossaint J, et al. Crucial role of SLP-76 and ADAP for neutrophil recruitment in mouse kidney ischemia-reperfusion injury. J Exp Med 2012;209:407-21
   PubMedGoogle Scholar
• Palatianos GM, Balentine G, Papadakis EG, et al. Neutrophil depletion reduces myocardial reperfusion morbidity. Ann Thorac Surg 2004;77:956-61
   PubMed Web of Science ®Google Scholar
• Litt MR, Jeremy RW, Weisman HF, et al. Neutrophil depletion limited to reperfusion reduces myocardial infarct size after 90 minutes of ischemia. Evidence for neutrophil-mediated reperfusion injury. Circulation 1989;80:1816-27
   PubMed Web of Science ®Google Scholar
• Tarzami ST, Miao W, Mani K, et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 2003;108:2387-92
   PubMed Web of Science ®Google Scholar
• Cugini D, Azzollini N, Gagliardini E, et al. Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney Int 2000;67:1753-61
   Google Scholar
• Xia M, Hyman BT. GROalpha/KC, a chemokine receptor CXCR2 ligand, can be a potent trigger for neuronal ERK1/2 and PI-3 kinase pathways and for tau hyperphosphorylation-a role in Alzheimer's disease? J Neuroimmunol 2002;122:55-64
   PubMedGoogle Scholar
• Bakshi P, Margenthaler E, Reed J, et al. Depletion of CXCR2 inhibits gamma-secretase activity and amyloid-beta production in a murine model of Alzheimer's disease. Cytokine 2011;53:163-9
   Google Scholar
• Semple BD, Bye N, Ziebell JM, Morganti-Kossmann MC. Deficiency of the chemokine receptor CXCR2 attenuates neutrophil infiltration and cortical damage following closed head injury. Neurobiol Dis 2010;40:394-403
   PubMed Web of Science ®Google Scholar
• Balentien E, Mufson BE, Shattuck RL, et al. Effects of MGSA/GRO alpha on melanocyte transformation. Oncogene 1991;6:1115-24
   PubMedGoogle Scholar
• Horton LW, Yu Y, Zaja-Milatovic S, et al. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res 2007;67:9791-9
   PubMedGoogle Scholar
• Raman D, Sobolik-Delmaire T, Richmond A. Chemokines in health and disease. Exp Cell Res 2011;317:575-89
   PubMed Web of Science ®Google Scholar
• Murphy C, McGurk M, Pettigrew J, et al. Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 2005;11:4117-27
   PubMed Web of Science ®Google Scholar
• Horikawa T, Kaizaki Y, Kato H, et al. Expression of interleukin-8 receptor A predicts poor outcome in patients with nasopharyngeal carcinoma. Laryngoscope 2005;115:62-7
   PubMedGoogle Scholar
• Robinson S, Cohen M, Prayson R, et al. Constitutive expression of growth-related oncogene and its receptor in oligodendrogliomas. Neurosurgery 2001;48:864-73
   PubMed Web of Science ®Google Scholar
• Bohrer LR, Schwertfeger KL. Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner. Mol Cancer Res 2012;10:1294-305
   PubMedGoogle Scholar
• Cataisson C, Ohman R, Patel G, et al. Inducible cutaneous inflammation reveals a protumorigenic role for keratinocyte CXCR2 in skin carcinogenesis. Cancer Res 2009;69:319-28
   PubMedGoogle Scholar
• Luan J, Shattuck-Brandt R, Haghnegahdar H, et al. Mechanism and biological significance of constitutive expression of MGSA/GRO chemokines in malignant melanoma tumor progression. J Leukoc Biol 1997;62:588-97
   PubMed Web of Science ®Google Scholar
• Maxwell PJ, Gallagher R, Seaton A, et al. HIF-1 and NF-kappaB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 2007;26:7333-45
   PubMed Web of Science ®Google Scholar
• Keane MP, Belperio JA, Xue YY, et al. Depletion of CXCR2 inhibits tumor growth and angiogenesis in a murine model of lung cancer. J Immunol 2004;172:2853-60
   PubMed Web of Science ®Google Scholar
• Wislez M, Fujimoto N, Izzo JG, et al. High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res 2006;66:4198-207
   PubMed Web of Science ®Google Scholar
• Miyazaki H, Patel V, Wang H, et al. Down-regulation of CXCL5 inhibits squamous carcinogenesis. Cancer Res 2006;66:4279-84
   PubMed Web of Science ®Google Scholar
• Begley LA, Kasina S, Mehra R, et al. CXCL5 promotes prostate cancer progression. Neoplasia 2008;10:244-54
   PubMed Web of Science ®Google Scholar
• Arenberg DA, Keane MP, DiGiovine B, et al. Epithelial-neutrophil activating peptide (ENA-78) is an important angiogenic factor in non-small cell lung cancer. J Clin Invest 1998;102:465-72
   PubMed Web of Science ®Google Scholar
• Jamieson T, Clarke M, Steele CW, et al. Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis. J Clin Invest 2012;122:3127-44
   PubMed Web of Science ®Google Scholar
• Acosta JC, O'Loghlen A, Banito A, et al. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell 2008;133:1006-18
   PubMed Web of Science ®Google Scholar
• Lazennec G, Richmond A. Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 2010;16:133-44
   PubMed Web of Science ®Google Scholar
• Kuwada Y, Sasaki T, Morinaka K, et al. Potential involvement of IL-8 and its receptors in the invasiveness of pancreatic cancer cells. Int J Oncol 2003;22:765-71
   PubMed Web of Science ®Google Scholar
• Hill KS, Gaziova I, Harrigal L, et al. Met receptor tyrosine kinase signaling induces secretion of the angiogenic chemokine interleukin-8/CXCL8 in pancreatic cancer. PLoS One 2012;7:e40420
   Google Scholar
• Frick VO, Rubie C, Wagner M, et al. Enhanced ENA-78 and IL-8 expression in patients with malignant pancreatic diseases. Pancreatology 2008;8:488-97
   PubMedGoogle Scholar
• Noh KW, Pungpapong S, Wallace MB, et al. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol 2006;4:782-9
   PubMedGoogle Scholar
• Ijichi H, Chytil A, Gorska AE, et al. Inhibiting CXCR2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. J Clin Invest 2011;121:4106-17
   PubMed Web of Science ®Google Scholar
• Li A, Cheng XJ, Moro A, et al. CXCR2-Dependent endothelial progenitor cell mobilization in pancreatic cancer growth. Transl Oncol 2011;4:20-8
   PubMedGoogle Scholar
• Singh S, Wu S, Varney M, et al. CXCR1 and CXCR2 silencing modulates CXCL8-dependent endothelial cell proliferation, migration and capillary-like structure formation. Microvasc Res 2011;82:318-25
   PubMedGoogle Scholar
• Matsuo Y, Campbell PM, Brekken RA, et al. K-Ras promotes angiogenesis mediated by immortalized human pancreatic epithelial cells through mitogen-activated protein kinase signaling pathways. Mol Cancer Res 2009;7:799-808
   PubMed Web of Science ®Google Scholar
• Blood CH, Zetter BR. Tumor interactions with the vasculature: angiogenesis and tumor metastasis. Biochim Biophys Acta 1990;1032:89-118
   PubMed Web of Science ®Google Scholar
• Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6
   PubMed Web of Science ®Google Scholar
• Acharyya S, Oskarsson T, Vanharanta S, et al. A CXCL1 paracrine network links cancer chemoresistance and metastasis. Cell 2012;150:165-78
   PubMed Web of Science ®Google Scholar
• White JR, Lee JM, Young PR, et al. Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration. J Biol Chem 1998;273:10095-8
   PubMed Web of Science ®Google Scholar
• Moss RB, Mistry SJ, Konstan MW, et al. Safety and early treatment effects of the CXCR2 antagonist SB-656933 in patients with cystic fibrosis. J Cyst Fibros 2012; published online 17 September 2012; doi: 10.1016/j.jcf.2012.08.016
   Google Scholar
• Bizzarri C, Pagliei S, Brandolini L, et al. Selective inhibition of interleukin-8-induced neutrophil chemotaxis by ketoprofen isomers. Biochem Pharmacol 2001;61:1429-37
   PubMedGoogle Scholar
• Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade. Oncol Rep 2005;13:559-83
   PubMed Web of Science ®Google Scholar
• Bertini R, Allegretti M, Bizzarri C, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci USA 2004;101:11791-6
   PubMed Web of Science ®Google Scholar
• Souza DG, Bertini R, Vieira AT, et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br J Pharmacol 2004;143:132-42
   PubMed Web of Science ®Google Scholar
• Garau A, Bertini R, Colotta F, et al. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 2005;30:125-31
   PubMed Web of Science ®Google Scholar
• Coelho FM, Pessini AC, Coelho AM, et al. Platelet activating factor receptors drive CXC chemokine production, neutrophil influx and edema formation in the lungs of mice injected with Tityus serrulatus venom. Toxicon 2007;50:420-7
   PubMedGoogle Scholar
• Zarbock A, Allegretti M, Ley K. Therapeutic inhibition of CXCR2 by Reparixin attenuates acute lung injury in mice. Br J Pharmacol 2008;155:357-64
   PubMed Web of Science ®Google Scholar
• Gorio A, Madaschi L, Zadra G, et al. Reparixin, an inhibitor of CXCR2 function, attenuates inflammatory responses and promotes recovery of function after traumatic lesion to the spinal cord. J Pharmacol Exp Ther 2007;322:973-81
   PubMedGoogle Scholar
• Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol 2004;76:441-50
   PubMed Web of Science ®Google Scholar
• Chapman RW, Phillips JE, Hipkin RW, et al. CXCR2 antagonists for the treatment of pulmonary disease. Pharmacol Ther 2009;121:55-68
   PubMed Web of Science ®Google Scholar
• Hidaka H, Ishiko T, Furuhashi T, et al. Curcumin inhibits interleukin 8 production and enhances interleukin 8 receptor expression on the cell surface:impact on human pancreatic carcinoma cell growth by autocrine regulation. Cancer 2002;95:1206-14
   PubMed Web of Science ®Google Scholar
• Kim J, Yip MLR, Shen X, et al. Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells. PLoS One 2012;7:e31004
   Google Scholar
• Park SH, Das BB, Casagrande F, et al. Structure of the chemokine receptor CXCR1 in phospholipid bilayers. Nature 2012;491:779-83
   PubMed Web of Science ®Google Scholar
• Addison CL, Daniel TO, Burdick MD, et al. The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity. J Immunol 2000;165:5269-77
   PubMed Web of Science ®Google Scholar
• Strieter RM, Belperio JA, Phillips RJ, Keane MP. CXC chemokines in angiogenesis of cancer. Semin Cancer Biol 2004;14:195-200
   PubMed Web of Science ®Google Scholar
• Du J, Luan J, Liu H, et al. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. J Leukoc Biol 2002;71:141-53
   PubMed Web of Science ®Google Scholar
• Horton LW, Yu Y, Zaja-Milatovic S, et al. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res 2007;67:9791-9
   PubMedGoogle Scholar
• Addison CL, Belperio JA, Burdick MD, Strieter RM. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 2004;4:28
   PubMedGoogle Scholar
• Donahue TR, Hines OJ. CXCR2 and RET single nucleotide polymorphisms in pancreatic cancer. World J Surg 2009;33:710-15
   PubMed Web of Science ®Google Scholar
• Kormann MSD, Hector A, Marcos V, et al. CXCR1 and CXCR2 haplotypes synergistically modulate cystic fibrosis lung disease. Eur Respir J 2012;39:1385-90
   PubMedGoogle Scholar